Mangoceuticals, Inc. MGRX
Misc Health and Biotechnology Services · IPO 2023 · data as of November 13, 2026
Mangoceuticals, Inc. (MGRX) is a healthcare company listed in the US with a market value of about $3M. In the twelve months to June 30, 2026 it had revenue of $315227 and net income of -$16M, a net margin of -5164.4%.
Its overall Stock Analiz score is 0.6 out of 5 (weak). The strongest part is financial health (2/5); the weakest is value (0/5).
Key numbers: a 5-year average ROIC of -285%.
About Mangoceuticals
Mangoceuticals is listed in the US and classified in misc health and biotechnology services, IPO year 2023. Revenue went from $8939 in 2022 to $456021 in 2025, growth of about 270.9% a year. It was profitable in 0 of the last 4 years in our data. Its share count rose by 1299% over three years (dilution for shareholders).
Score: 0.6 / 5
Checks passed
- 3-year revenue growth above 10% a year
- More cash than debt, or low debt to equity
- Liabilities below 60% of assets
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- Revenue growth above 10% last year
- Profit margin improving
- 3-year free cash flow growth above 10% a year
Valuation
Growth and quality
Financials, last 4 years
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | $315227 | $456021 | $615873 | $731493 | $8939 |
| Net income | -$16M | -$21M | -$9M | -$9M | -$2M |
| Free cash flow | -$4M | — | — | -$7M | -$1M |
| EPS (diluted) | $-1.01 | $-2.17 | $-4.80 | $-8.58 | $-2.85 |
| Net margin | -5164.4% | -4526.8% | -1413.6% | -1259.4% | -22352.1% |
| ROIC | — | -91.9% | -44.5% | -806.1% | -196.8% |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
Frequently asked questions
Does Mangoceuticals pay a dividend?
Not currently.
Is Mangoceuticals a good stock to buy?
We do not give buy or sell advice. Mangoceuticals scores 0.6 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.